Treatment News : FDA Review of HIV Lipodystrophy Drug Is Delayed

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 26, 2010

FDA Review of HIV Lipodystrophy Drug Is Delayed

Montreal-based Theratechnologies announced yesterday that the U.S. Food and Drug Administration (FDA) will reschedule its meeting with independent experts to help decide whether to approve Egrifta (tesamorelin) for the treatment of HIV-associated lipodystrophy. Originally scheduled for Wednesday, February 24, the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee is being delayed for procedural reasons, Theratechnologies reports, not because of concerns surrounding tesamorelin’s safety or efficacy.

Theratechnologies submitted its request for approval—known as a new drug application (NDA)—to the FDA on May 29, 2009, for Egrifta. The drug works by prompting the body to release growth hormone, which has been shown to diminish abnormal fat accumulation—a hallmark symptom of HIV-associated lipodystrophy.

Once approved, Egrifta will be marketed and sold in the U.S. by Rockland, Massachusetts-based EMD Serono. 

Though the FDA has not yet scheduled an alternative date for the advisory committee, March 29 is the target date for the FDA to complete its review of Egrifta’s NDA and either approve or deny the drug’s use for HIV-positive people with lipodystrophy.

Search: Egrifta, tesamorelin, Theratechnologies, EMD Serono, FDA, approval, lipodystrophy, growth hormone


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    july8th69
    brooklyn
    New York


    Deelight4u
    BROOKLYN
    New York


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.